Puma Biotechnology, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDPuma Biotechnology, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 81), indicating clear outperformance against the broad market. Earnings contraction of 224% provides fundamental context to the price action. Investors should exercise caution due to high volatility (69% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $7.30 | +11.05% | ABOVE |
| 50 SMA | $7.29 | +11.27% | ABOVE |
| 100 SMA | $6.98 | +16.27% | ABOVE |
| 150 SMA | $6.60 | +22.93% | ABOVE |
| 200 SMA | $6.20 | +30.74% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PBYI in an uptrend right now?
PBYI has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, PBYI is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is PBYI overbought or oversold?
PBYI's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is PBYI outperforming the market?
PBYI has a Relative Strength (RS) Rating of 81 out of 99. Yes, PBYI is a market leader, outperforming 81% of all stocks over the past 12 months.
Where is PBYI in its 52-week range?
PBYI is trading at $8.11, which is 96% of its 52-week high ($8.41) and 94% above its 52-week low ($3.03).
How volatile is PBYI?
PBYI has a Beta of 0.61 and 52-week volatility of 69%. It's less volatile than the S&P 500 - generally more stable.